Diamond Biofund (TPE:6901) Revenue: NT$0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6901 Diamond Biofund Inc TPE:6901
16 GF Score
Price NT$18.35
! 1 Warning Sign
View Full Analysis

What is Diamond Biofund Revenue?

Diamond Biofund TPE:6901 -3.93% 16 Revenue is NT$0.00 Mil as of Dec. 2025. GuruFocus rates TPE:6901 with a GF Score™ of 16/100. The stock has 1 warning sign investors should review.

Diamond Biofund's revenue for the three months ended in Dec. 2025 was NT$0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.00 Mil. Diamond Biofund's Revenue per Share for the three months ended in Dec. 2025 was NT$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


Diamond Biofund  (TPE:6901) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Diamond Biofund Revenue Related Terms


Diamond Biofund Revenue Historical Data

* Premium members only.

The historical data trend for Diamond Biofund's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diamond Biofund Revenue Chart

Diamond Biofund Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Diamond Biofund Quarterly Data
Dec19 Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TPE:6901 vs BLK, BX, KKR: Revenue Comparison

For the Asset Management subindustry, Diamond Biofund's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamond Biofund Revenue vs Asset Management Industry

For the Asset Management industry and Financial Services sector, Diamond Biofund's Revenue distribution charts can be found below:

* The bar in red indicates where Diamond Biofund's Revenue falls into.


TPE:6901
16GF Score
Diamond Biofund Inc TPE:6901
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diamond Biofund Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of NT$0.00 Mil mean?
Diamond Biofund (TPE:6901) has a Revenue of NT$0.00 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Diamond Biofund and its competitors.
Is Diamond Biofund's Revenue too high?
Diamond Biofund's current Revenue is NT$0.00 Mil. Overall, Diamond Biofund has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Diamond Biofund's Revenue compare to BLK and BX?
Diamond Biofund's Revenue of NT$0.00 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for an Asset Management company?
A good Revenue depends on the Asset Management industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Diamond Biofund and its competitors. Diamond Biofund's current Revenue is NT$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamond Biofund stock overvalued right now?
Diamond Biofund (TPE:6901) has a current Revenue of NT$0.00 Mil. The current Revenue is NT$0.00 Mil. Diamond Biofund's overall GF Score™ is 16/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Diamond Biofund (TPE:6901), the current Revenue is NT$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Diamond Biofund Business Description

Address Zhongxiao West Road, 34th Floor, No. 66, Section 1, Zhongzheng District, Taipei, TWN, 100
Diamond Biofund Inc is a sustainable biotech venture capital that focuses on the field of biotechnology and medical investment, targeting competitive investment targets, including new drug research and development, high-end medical equipment, medical service technology, medical access, agricultural biotechnology.
16GF Score

Get the complete analysis for TPE:6901

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.35
Price